| |
Antiplatelet group
|
Non-antiplatelet group
|
p value
|
|---|
|
Number
|
31
|
28
| |
|
Age
|
73 (68–78)
|
71 (58.5–80)
|
0.27
|
|
Older age (%)
|
54.8
|
42.9
|
0.44
|
|
Sex (male, %)
|
80.7
|
64.3
|
0.22
|
|
Etiology of ESRD (%)
|
|
DN
|
48.4
|
32.1
|
0.20
|
|
NS
|
25.8
|
21.4
|
0.69
|
|
CGN
|
9.7
|
21.4
|
0.21
|
|
ADPKD
|
3.2
|
0
|
0.34
|
|
IgAN
|
6.5
|
3.6
|
0.62
|
|
Other or unknown
|
6.5
|
21.4
|
0.093
|
|
Smoking history (%)
|
80.7
|
46.4
|
0.008
|
|
DM (%)
|
61.3
|
53.6
|
0.60
|
|
Dyslipidemia (%)
|
74.2
|
39.3
|
0.009
|
|
CVD (%)
|
80.7
|
25.0
|
< 0.001
|
|
IHD
|
58.1
|
10.7
|
< 0.001
|
|
CHF
|
16.1
|
10.7
|
0.54
|
|
Stroke
|
22.6
|
0
|
0.007
|
|
PAD (%)
|
22.6
|
3.6
|
0.55
|
|
RASI (%)
|
45.2
|
60.7
|
0.30
|
|
Statin (%)
|
29.0
|
75.0
|
< 0.001
|
|
Warfarin (%)
|
6.5
|
10.7
|
0.67
|
|
ESA
|
|
Epoetin α or β (IU/week)
|
3750.0 ± 1068.5
|
2750.0 ± 975.4
|
0.51
|
|
Darbepoetin α (μg/week)
|
33.1 ± 9.7
|
47.4 ± 9.4
|
0.29
|
|
CERA (μg/2 week)
|
50
|
75
|
–
|
|
Hb (g/dl)
|
10.6 ± 0.3
|
10.1 ± 0.29
|
0.28
|
|
Platelet (× 103/μl)
|
19.8 ± 1.2
|
17.9 ± 1.3
|
0.28
|
|
PT-INR
|
1.0 ± 0.1
|
1.1 ± 0.1
|
0.50
|
|
CRP (mg/dl)
|
0.6 ± 0.3
|
0.8 ± 0.3
|
0.71
|
|
Dialysis duration (month)
|
31.8 ± 33.2
|
20.8 ± 27.0
|
0.42
|
|
AVF anastomosis type (%)
|
|
Radiocephalic
|
71.0
|
92.9
|
0.031
|
|
Brachiocephalic
|
25.8
|
7.1
|
0.056
|
|
Radiobasilic
|
3.2
|
0
|
0.34
|
|
Quantity of blood flow (ml/min)
|
194.1 ± 6.5
|
190 ± 7.6
|
0.69
|
|
Flow volume (ml/min)
|
|
Before VAIVT
|
461.8 ± 86.1
|
373.1 ± 88.5
|
0.47
|
|
After VAIVT
|
816.2 ± 172.9
|
872.1 ± 177.9
|
0.82
|
|
VAF
|
|
Thrombosis (%)
|
19.4
|
10.7
|
0.48
|
|
Adverse event (%)
|
|
Serious bleeding event
|
|
Intracranial
|
0
|
0
|
–
|
|
Gastrointestinal
|
0
|
0
|
–
|
|
CVD event after VAIVT
|
|
IHD
|
19.4
|
3.6
|
0.061
|
|
CHF
|
6.5
|
3.6
|
0.62
|
|
Stroke
|
3.2
|
0
|
0.34
|
- We defined individuals aged > 71 years as “the older age”
- ESRD end-stage renal disease, DN diabetic nephropathy, NS nephrosclerosis, CGN chronic glomerulonephritis, ADPKD autosomal dominant polycystic kidney disease, IgAN IgA nephropathy, DM diabetes mellitus, CVD cardiovascular disease, IHD ischemic heart disease, CHF congestive heart failure, PAD peripheral artery disease, RASI renin–angiotensin–aldosterone system inhibitor, ESA erythropoiesis-stimulating agent, CERA continuous erythropoietin receptor activator, AVF arteriovenous fistula, VAIVT vascular access intervention therapy, VAF vascular access failure
